Guard Therapeutics International AB (publ)

GUARD.ST

Biotechnology · Healthcare

Price

kr 1.39

+0.06 (+4.21%)

Market Cap

kr 28.0M

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count falling — buybacks

−83.7% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 110.3M (2021) → 18.0M (2025)

Guard Therapeutics International AB is a small Swedish biotech company focused on developing drugs to protect the kidneys during medical procedures. Its lead drug candidate, ROSgard, is designed to reduce kidney damage that can occur when patients undergo heart surgery — a serious complication that affects a significant number of surgical patients each year. The company is in the clinical-stage, meaning it does not yet sell any approved products.

Guard Therapeutics earns no product revenue at this stage and funds its operations through equity raises and grants, which is typical for early-stage biotech firms. It operates primarily in Sweden and conducts clinical trials across European medical centers. The company's entire value rests on the success of ROSgard in clinical development, which creates significant risk — if trials fail or regulatory approval is not obtained, the company has no fallback revenue stream. The key near-term driver is clinical trial data that will determine whether ROSgard can advance toward regulatory submission.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+88.8% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$96M/ year

↑ Rising (+6% vs prior year)

R&D investment increasing — building for the future

Insider Activity

51.8%ownership

Insiders own a meaningful stake in the company

Cash Runway

~14 months

$41M cash & investments

Adequate runway but may need to raise capital within 2 years

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-17.9%

Weak — -17.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

—

Data not available

EPS YoY

N/A

—

Data not available

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial